Rgenix Reports Phase I Data for Cancer Compound RGX-104

Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. To read the full article, please click here.

The release as fetched from its publisher. inspirna.com ↗